Latest Financial Stability News

FINEOS Corporation reports robust FY25 financial performance, driven by subscription revenue growth and embedded AI innovations, setting a confident outlook through FY27.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

Key Petroleum Ltd has completed a modest 3% share placement but will not proceed with the remaining 13%, leaving questions over its funding strategy.

OZZ Resources Limited has announced a fully underwritten entitlement offer to raise approximately $1.07 million, aiming to convert debt and fund project opportunities while addressing its ongoing ASX suspension. The offer carries significant risks including potential dilution and the threat of delisting if compliance is not met by June 2026.

Bank of Queensland Limited announces a fully franked quarterly distribution of AUD 1.3218 per Capital Note 3 security, payable mid-June 2026. The distribution reflects a 5.3% annualised rate tied to the 3-month BBSW plus margin.

Kina Securities Limited has launched its inaugural unsecured subordinated bond issue worth PGK 235 million, offering a fixed 7.55% coupon over 10 years, marking a significant step in Papua New Guinea's capital markets.

Oneview Healthcare has successfully raised A$19 million through a two-tranche placement and launched a Security Purchase Plan to further strengthen its financial position and accelerate AI development.

TZ Limited has responded to ASX queries over the deferral of a A$2.75 million debt repayment, asserting the delay was already well disclosed and unlikely to impact its share price materially.

Pure Foods Tasmania reports a significant operational turnaround in 1H FY26, driven by strategic cost reductions, expanded distribution deals with major retailers, and the acquisition of premium ice cream brand Elato.

The Star Entertainment Group reported a 10% drop in H1 FY26 revenue, offset by a 71% improvement in EBITDA, while navigating ongoing licence suspensions and a critical refinancing process.

ClearVue Technologies reported a 9% reduced half-year loss of $5.25 million, while pushing forward with significant advancements in its solar glass technology and expanding global licensing partnerships.

Nexalis Therapeutics reported a widening loss of $1.83 million for 2025, reflecting increased investment in product development and marketing. Despite the loss, the company boosted its cash reserves through equity raises and borrowings.